Clinical trials have tested doses up to 12 mg, with structured increases over about 16 weeks before reaching a steady maintenance dose
If you are interested in learning more about metabolic health and weight loss, please consult us at Dignity Weight Center
Many insurance plans, however, will only pay for GLP-1s if a person has a diagnosis of diabetes, not obesity
NylanderMFrssingSKistorpCFaberJSkoubyS
Treatment evolves as progress is made, ensuring that each patient continues moving toward their goals at a safe, sustainable pace
Safety risks in the GLP-1 market: an update on weight loss medication, May 2026 Drug shortages and coverage gaps have led to criminal counterfeiters exploiting Americans demand for blockbuster diabetes and weight loss drugs made with semaglutide and tirzepatide